{"id":"NCT02247401","sponsor":"AbbVie","briefTitle":"Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt","officialTitle":"An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-04","primaryCompletion":"2016-08-01","completion":"2016-08-01","firstPosted":"2014-09-25","resultsPosted":"2017-07-27","lastUpdate":"2021-07-30"},"enrollment":160,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HCV","Hepatitis C Infection","Genotype 4"],"interventions":[{"type":"DRUG","name":"2 DAA","otherNames":[]},{"type":"DRUG","name":"RBV","otherNames":[]}],"arms":[{"label":"Arm A","type":"ACTIVE_COMPARATOR"},{"label":"Arm B","type":"ACTIVE_COMPARATOR"},{"label":"Arm C","type":"ACTIVE_COMPARATOR"}],"summary":"This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm","timeFrame":"12 weeks after last dose","effectByArm":[{"arm":"Arm A","deltaMin":94,"sd":null},{"arm":"Arm B","deltaMin":96.8,"sd":null},{"arm":"Arm C","deltaMin":93.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28404110"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":100},"commonTop":["HEADACHE","FATIGUE","PRURITUS","DYSPEPSIA","ABDOMINAL PAIN UPPER"]}}